References
1. Huybrechts KF, Palmsten K, Mogun H, et al. National trends in
antidepressant medication treatment among publicly insured pregnant
women. Gen Hosp Psychiatry. 2013;35(3):265-271.
2. Zoega H, Kieler H, Norgaard M, et al. Use of SSRI and SNRI
Antidepressants during Pregnancy: A Population-Based Study from Denmark,
Iceland, Norway and Sweden. PLoS One. 2015;10(12):e0144474.
3. Charlton RA, Jordan S, Pierini A, et al. Selective serotonin reuptake
inhibitor prescribing before, during and after pregnancy: a
population-based study in six European regions. BJOG.2015;122(7):1010-1020.
4. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin:
news from mouse molecular genetics. Nat Rev Neurosci.2003;4(12):1002-1012.
5. Sujan AC, Oberg AS, Quinn PD, D’Onofrio BM. Annual Research Review:
Maternal antidepressant use during pregnancy and offspring
neurodevelopmental problems - a critical review and recommendations for
future research. J Child Psychol Psychiatry. 2019;60(4):356-376.
6. Man KKC, Chan EW, Ip P, et al. Prenatal antidepressant exposure and
the risk of attention-deficit hyperactivity disorder in children: A
systematic review and meta-analysis. Neurosci Biobehav Rev.2018;86:1-11.
7. Hjorth S, Bromley R, Ystrom E, Lupattelli A, Spigset O, Nordeng H.
Use and validity of child neurodevelopment outcome measures in studies
on prenatal exposure to psychotropic and analgesic medications - A
systematic review. PLoS One. 2019;14(7):e0219778.
8. Lupattelli A, Wood M, Ystrom E, Skurtveit S, Handal M, Nordeng H.
Effect of Time-Dependent Selective Serotonin Reuptake Inhibitor
Antidepressants During Pregnancy on Behavioral, Emotional, and Social
Development in Preschool-Aged Children. J Am Acad Child Adolesc
Psychiatry. 2018;57(3):200-208.
9. Sayal K, Prasad V, Daley D, Ford T, Coghill D. ADHD in children and
young people: prevalence, care pathways, and service provision.Lancet Psychiatry. 2018;5(2):175-186.
10. Magnus P, Birke C, Vejrup K, et al. Cohort Profile Update: The
Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol.2016;45(2):382-388.
11. Magnus P, Irgens LM, Haug K, et al. Cohort profile: the Norwegian
Mother and Child Cohort Study (MoBa). Int J Epidemiol.2006;35(5):1146-1150.
12. Irgens LM. The Medical Birth Registry of Norway. Epidemiological
research and surveillance throughout 30 years. Acta Obstet Gynecol
Scand. 2000;79(6):435-439.
13. Norwegian Institute of Public Health. Norwegian Prescription
Database (NorPD).
https://www.fhi.no/en/hn/health-registries/norpd/. Published 2019.
Accessed 19 March, 2019.
14. Bakken IJ, Suren P, Haberg SE, Cappelen I, Stoltenberg C. [The
Norwegian patient register–an important source for research].Tidsskr Nor Laegeforen. 2014;134(1):12-13.
15. Hernan MA, Alonso A, Logan R, et al. Observational studies analyzed
like randomized experiments: an application to postmenopausal hormone
therapy and coronary heart disease. Epidemiology.2008;19(6):766-779.
16. Wood ME, Lapane KL, van Gelder M, Rai D, Nordeng HME. Making fair
comparisons in pregnancy medication safety studies: An overview of
advanced methods for confounding control. Pharmacoepidemiol Drug
Saf. 2018;27(2):140-147.
17. Strand BH, Dalgard OS, Tambs K, Rognerud M. Measuring the mental
health status of the Norwegian population: a comparison of the
instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). Nord J
Psychiatry. 2003;57(2):113-118.
18. Tambs K, Moum T. How well can a few questionnaire items indicate
anxiety and depression? Acta Psychiatr Scand. 1993;87(5):364-367.
19. Norwegian Institute of Public Health. The Nowegian Mother and Child
Cohort Study. Questionnaires. Norwegian Institute of Public Health.
https://fhi.no/en/studies/moba/for-forskere-artikler/questionnaires-from-moba/.
Accessed August 5, 2019.
20. WHO Collaborating Centre for Drugs Statistics Methodology. ATC/DDD
index 2012. http://www.whocc.no/atc_ddd_index/. Accessed 17 March,
2017.
21. Skurtveit S, Selmer R, Tverdal A, Furu K, Nystad W, Handal M. Drug
exposure: inclusion of dispensed drugs before pregnancy may lead to
underestimation of risk associations. J Clin Epidemiol.2013;66(9):964-972.
22. Lupattelli A, Chambers CD, Bandoli G, Handal M, Skurtveit S, Nordeng
H. Association of Maternal Use of Benzodiazepines and Z-Hypnotics During
Pregnancy With Motor and Communication Skills and
Attention-Deficit/Hyperactivity Disorder Symptoms in Preschoolers.JAMA Netw Open. 2019;2(4):e191435.
23. Ørstavik R, Gustavson K, Rohrer-Baumgartner N, et al. ADHD i
Norge. Folkehelseinstituttet 2016.
24. ADHD and hyperkinetic disorder. In: Rutter’s Child and
Adolescent Psychiatry. 738-756.
25. Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised
Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability,
and criterion validity. J Abnorm Child Psychol.1998;26(4):257-268.
26. Textor J, Hardt J, Knuppel S. DAGitty: a graphical tool for
analyzing causal diagrams. Epidemiology. 2011;22(5):745.
27. Bateman BT, Mhyre JM, Hernandez-Diaz S, et al. Development of a
comorbidity index for use in obstetric patients. Obstet Gynecol.2013;122(5):957-965.
28. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. The lifetime
history of major depression in women. Reliability of diagnosis and
heritability. Arch Gen Psychiatry. 1993;50(11):863-870.
29. Austin PC, Stuart EA. Moving towards best practice when using
inverse probability of treatment weighting (IPTW) using the propensity
score to estimate causal treatment effects in observational studies.Stat Med. 2015;34(28):3661-3679.
30. Robins JM, Hernan MA, Brumback B. Marginal structural models and
causal inference in epidemiology. Epidemiology.2000;11(5):550-560.
31. Rubin DB. Multiple imputation for nonresponse in surveys. New
York: Wiley; 1987.
32. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for
missing data in epidemiological and clinical research: potential and
pitfalls. BMJ. 2009;338:b2393.
33. Moodie EE, Delaney JA, Lefebvre G, Platt RW. Missing confounding
data in marginal structural models: a comparison of inverse probability
weighting and multiple imputation. The international journal of
biostatistics. 2008;4(1):Article 13.
34. Nilsen RM, Vollset SE, Gjessing HK, et al. Self-selection and bias
in a large prospective pregnancy cohort in Norway. Paediatr
Perinat Epidemiol. 2009;23(6):597-608.
35. Biele G, Gustavson K, Czajkowski NO, et al. Bias from self selection
and loss to follow-up in prospective cohort studies. Eur J
Epidemiol. 2019;34(10):927-938.
36. Malm H, Brown AS, Gissler M, et al. Gestational Exposure to
Selective Serotonin Reuptake Inhibitors and Offspring Psychiatric
Disorders: A National Register-Based Study. J Am Acad Child
Adolesc Psychiatry. 2016;55(5):359-366.
37. Grzeskowiak LE, Morrison JL, Henriksen TB, et al. Prenatal
antidepressant exposure and child behavioural outcomes at 7 years of
age: a study within the Danish National Birth Cohort. BJOG.2016;123(12):1919-1928.
38. Jiang HY, Peng CT, Zhang X, Ruan B. Antidepressant use during
pregnancy and the risk of attention-deficit/hyperactivity disorder in
the children: a meta-analysis of cohort studies. BJOG.2018;125(9):1077-1084.
39. Hernán MA. The Hazards of Hazard Ratios. Epidemiology.2010;21(1):13-15.
40. Boukhris T, Sheehy O, Berard A. Antidepressant Use in Pregnancy and
the Risk of Attention Deficit with or without Hyperactivity Disorder in
Children. Paediatr Perinat Epidemiol. 2017.
41. Man KKC, Chan EW, Ip P, et al. Prenatal antidepressant use and risk
of attention-deficit/hyperactivity disorder in offspring: population
based cohort study. BMJ. 2017;357:j2350.
42. Sujan AC, Rickert ME, Oberg AS, et al. Associations of Maternal
Antidepressant Use During the First Trimester of Pregnancy With Preterm
Birth, Small for Gestational Age, Autism Spectrum Disorder, and
Attention-Deficit/Hyperactivity Disorder in Offspring. JAMA.2017;317(15):1553-1562.
43. Laugesen K, Olsen MS, Telen Andersen AB, Froslev T, Sorensen HT. In
utero exposure to antidepressant drugs and risk of attention deficit
hyperactivity disorder: a nationwide Danish cohort study. BMJ
open. 2013;3(9):e003507.
44. El Marroun H, White T, Verhulst FC, Tiemeier H. Maternal use of
antidepressant or anxiolytic medication during pregnancy and childhood
neurodevelopmental outcomes: a systematic review. Eur Child
Adolesc Psychiatry. 2014;23(10):973-992.
45. Maoz H, Goldstein T, Goldstein BI, et al. The effects of parental
mood on reports of their children’s psychopathology. J Am Acad
Child Adolesc Psychiatry. 2014;53(10):1111-1122.e1115.
46. Galéra C, Côté SM, Bouvard MP, et al. Early Risk Factors for
Hyperactivity-Impulsivity and Inattention Trajectories From Age 17
Months to 8 Years. Arch Gen Psychiatry. 2011;68(12):1267-1275.
47. Schrantee A, Lucassen PJ, Booij J, Reneman L. Serotonin transporter
occupancy by the SSRI citalopram predicts default-mode network
connectivity. Eur Neuropsychopharmacol. 2018;28(10):1173-1179.
48. Samuele Cortese, M.D., Ph.D. ,, Clare Kelly, Ph.D. ,, Camille
Chabernaud, Ph.D. ,, et al. Toward Systems Neuroscience of ADHD: A
Meta-Analysis of 55 fMRI Studies. Am J Psychiatry.2012;169(10):1038-1055.
49. Eilertsen EM, Gjerde LC, Kendler KS, et al. Development of ADHD
symptoms in preschool children: Genetic and environmental contributions.
2019;31(4):1299-1305.